Sex-based outcomes after PCI in high-bleeding risk patients: Results from the Onyx ONE Clear trial
Roxana Mehran, M.D., MSCAI1, David E. Kandzari, M.D., FSCAI2, Ajay J. Kirtane, M.D., FSCAI3, Matthew J. Price, MD4, Daniel I. Simon, M.D.5, Azeem Latib, M.D., FSCAI6, Elvin Kedhi, MD, PhD7, Alexandre Abizaid, M.D.8, Azfar Zaman, MD9, Maria Parke10, Te-Hsin Lung10, Stephan Windecker, M.D.11 and Gregg W. Stone, M.D.12, (1)Icahn School of Medicine at Mount Sinai, New York, NY, (2)Piedmont Heart Institute, Atlanta, GA, (3)NewYork-Presbyterian Columbia University Irving Medical Center, New York, NY, (4)Scripps Clinic Medical Group, La Jolla, CA, (5)University Hospitals Cleveland Medical Center, Cleveland, OH, (6)Montefiore Medical Center, Bronx, NY, (7)Université Libre de Brussels, Brussels, Belgium, (8)Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, (9)Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom, (10)Medtronic, Santa Rosa, CA, (11)The University of Bern, Bern, Switzerland, (12)Icahn School of Medicine at Mount Sinai, New York City, NY